Figure 1.

Polymer formulated VEEV-based saRNA induces a high antigen-specific humoral response

Groups of n = 5 BALB/c mice were immunized 3 times 3 weeks apart with escalating doses of polymer formulated (PLX) VEEV-based saRNA encoding the ConSOSL.UFO.664 gp140 protein (PLX A.I.R/VEEV-gp140) and compared to unformulated VEEV-gp140. A PLX SFV-based saRNA encoding H1N1/Cf7-HA (PLX A.I.R/SFV-H1N1/Cf7-HA) was included as a positive control group. (A) The immunization schedule is depicted. (B) The specific IgG titers against H1N1/Cf7-HA and ConSOSL.UFO.664 were determined by ELISA. The RNA dose used for each group of animals is indicated under the x axis. For clarity, only p values corresponding to the last time point are indicated. (C) HA- and gp140-specific IFN-γ ELISpots are reported as spleen forming units (SFU)/10⁶ splenocytes. ELISpots were performed at week 8 after euthanasia. (D) The antigen-specific vaginal IgG was determined by ELISA. (C and D) Box and whiskers, with median, min-max, and 25^th–75^th percentile. Mann-Whitney unpaired t test, p values: ∗<0.05, ∗∗<0.01.